YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Injured by Aranesp?
Aranesp (generic: darbepoetin alfa) is approved to treat anemia caused by chemotherapy. Anemia is a common side effect of chemotherapy, which can damage the production of red blood cells. In anemia, the blood is lacking in healthy red blood cells, which transport oxygen to organs. The FDA approved Aranesp on September 17, 2001.On January 14, 2005 Amgen and the FDA sent letters to doctors advising them of a revision to the warning label for Aranesp. Two new studies with other drugs in the same class of Aranesp, known as erythropoietic drugs, have shown that using the drugs at higher-than-recommended doses increases the risk of adverse effects including blood clots and death.
Although the studies were conducted with other drugs (Eprex and NeoRecormon), Amgen has incorporated this information into the prescribing information for Aranesp to alert doctors to these potential risks.
Other life threatening side effects of Aranesp include cardiac arrest; hypertension; vascular thrombosis and convulsions.
If you or a loved one took Aranesp and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
AranespRSS Feed
Study Says Genetic Tests May Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Jun 3, 2008 | Parker Waichman Alonso LLP
Some cancer patients treated with the anemia drugs Procrit, Aranesp and Epogen could experience increased tumor growth. However, researcher recently reported that there may be a way to predict which cancer patients are at risk for this devastating side effect.Procrit, Aranesp and Epogen are known as an erythropoiesis-stimulating agent (ESA). All are made by Amgen, but Procrit is sold by Johnson & Johnson subsidiary Ortho Biotech under a licensing agreement. ESAs are a...
Congress Investigates Procrit, Epogen and Aranesp Marketing
Apr 2, 2008 | Parker Waichman Alonso LLP
Two members of Congress are looking into to allegations that the marketing of Procrit, Aranesp and Epogen encouraged overuse of the anemia drugs, placing some patients in danger. Reps. John Dingell and Bart Stupak, both Michigan Democrats, sent letters to Amgen and Johnson & Johnson on Monday, suggesting their marketing campaigns for Procrit, Aranesp and Epogen convinced physicians to prescribe the drugs at unsafe dosages. Procrit, Aranesp and Epogen are known as an...
Procrit, Aranesp, Epogen Should Be Allowed for Cancer Patients, With Some Restrictions, FDA Panel Says
Mar 13, 2008 | Parker Waichman Alonso LLP
An advisory panel has weighed in on the safety issues surrounding Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients and others. While the Food and Drug Administration (FDA) advisory panel did not call on the agency to rescind the approval of Procrit, Aranesp and Epogen to treat cancer patients, it did recommend more limited restrictions on the drugs. Procrit, Aranesp and Epogen are known as an erythropoiesis-stimulating agent (ESA). All are made by...
Procrit, Aranesp, Epogen Could be Restricted by FDA
Mar 12, 2008 | Parker Waichman Alonso LLP
Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients, could soon have new restrictions imposed on them by the Food and Drug Administration (FDA). Late last week, the FDA announced a new black box warning for Procrit, Aranesp and Epogen regarding their association with shortened survival and increased tumor growth in some cancer patients. Now there is speculation that the FDA is getting ready to rescind it approval of Procrit, Aranesp and Procrit to treat...
Aranesp, Epogen, Procrit Get Another Black Box Warning
Mar 10, 2008 | Parker Waichman Alonso LLP
Aranesp, Epogen and Procrit, drugs used to treat anemia in patients undergoing chemotherapy, will soon bear new black box warnings that they may shorten survival time in patients with certain types of tumors. Amgen's Aranesp and Epogen, and Johnson & Johnson's Procrit, have been under scrutiny for some time after several studies showed some patients treated with the drugs die sooner than others. In addition to the warning on survival time, the new black box warning for Aranesp,...
Aranesp
Quick Facts
Aranesp Reference Guide
Generic Name
Darbepoetin alfa
Date Approved
September 17, 2001
Manufacturer
Amgen, Inc
Status
On the market
1/14/05 updated label
Approved Uses
Anemia
Serious Side Effects
Blood clots
Hypertension
Cardiac arrest
Acute Myocardial Infarction
Vascular Thrombosis
Convulsions
Related Topics
Blood Clots
Defective Drugs
Diseases
Darbepoetin alfa
Date Approved
September 17, 2001
Manufacturer
Amgen, Inc
Status
On the market
1/14/05 updated label
Approved Uses
Anemia
Serious Side Effects
Blood clots
Hypertension
Cardiac arrest
Acute Myocardial Infarction
Vascular Thrombosis
Convulsions
Related Topics
Blood Clots
Defective Drugs
Diseases
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS